Bezlotoxumab reduces odds of recurrent C. difficile infection in transplant recipients

Bezlotoxumab reduces odds of recurrent C. difficile infection in transplant recipients

Bezlotoxumab significantly reduced the incidence of recurrent Clostridioides difficile infection among solid-organ transplant and hematopoietic-cell transplant recipients, according to a study published in Open Forum Infectious Diseases.“Solid-organ and hematopoietic-cell transplant recipients are at high-risk for recurrent Clostridioides difficile infection and poor outcomes associated with these infections,” Tanner M. Johnson, PharmD, AAHIVP, a PGY2 infectious disease pharmacy resident at the University of Colorado Hospital, and colleagues wrote.“This study initiallyRead More

Share on facebook
Share on twitter
Share on linkedin